Therapeutic potential of PLK1 inhibition in triple-negative breast cancer

• Published in: Laboratory investigation Vol. 99; no. 9; pp. 1275 - 1286
• Main Authors: Ueda, Ai, Oikawa, Keiki, Fujita, Koji, Ishikawa, Akio, Sato, Eiichi, Ishikawa, Takashi, Kuroda, Masahiko, Kanekura, Kohsuke
• Format: Journal Article
• Language: English
• Published: New York Elsevier Inc 01.09.2019; Nature Publishing Group US; Nature Publishing Group
• Subjects: 13/31; 13/51; 13/89; 13/95; 14/28; 631/67/1059/602; 692/699/67/1347; 96/2; 96/35; Apoptosis; Breast - metabolism; Breast cancer; Cell Cycle Proteins - antagonists & inhibitors; Cell Cycle Proteins - genetics; Cell Cycle Proteins - metabolism; Cell Line, Tumor; Deoxyribonucleic acid; DNA; Female; Gene Knockdown Techniques - methods; Humans; In vivo methods and tests; Inhibition; Inhibitors; Kinases; Laboratory Medicine; Mammary gland; Mammary glands; Medicine; Medicine & Public Health; Mitosis; Molecular Targeted Therapy; Pathology; Polo-like kinase; Polo-Like Kinase 1; Polyploidy; Protein Serine-Threonine Kinases - antagonists & inhibitors; Protein Serine-Threonine Kinases - genetics; Protein Serine-Threonine Kinases - metabolism; Proto-Oncogene Proteins - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Proto-Oncogene Proteins - metabolism; RNA, Small Interfering - genetics; siRNA; Therapeutic applications; Therapy; Triple Negative Breast Neoplasms - metabolism; Tumors

Triple negative breast cancer (TNBC) is responsible for significant number of breast cancer-associated deaths because of lacking of successful molecular-targeted therapy. To explore a therapeutic target for TNBC, we performed a siRNA-mediated knockdown screening and identified Polo-like kinase 1 (PL...